ERBB2 and neoplasm: For HER2-positive breast cancer, the recommended first-line treatment consists of trastuzumab in combination with cytotoxic agents, i.e., a taxane such as paclitaxel or docetaxel, considering a better tumor response, progression-free survival and overall survival compared with the cytotoxic agent alone [8].